8-K ·Filed Jul 1, 2026

CRMD

CorMedix Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001410098-26-000037
8-K material event: Items 4.01
Actionable Insight • Neutral

Monitor the next 10-Q filing for updates on remediation of the material weakness and any further auditor-related disclosures. The appointment of EY may improve audit credibility, but the pattern of auditor changes warrants close attention to financial reporting quality.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
CRMD ▼ -8.26% at T+60d
NEUTRAL call ✗ call lost -8.26% · α vs SPY -11.22% · entry $8.47 → $7.77
Entry anchored
Jul 1, 06:48 AM ET
via exchange tick
T+1d
+3.31%
call +3.31% · α +3.44%
$8.75
settled 3mo ago
T+5d
+4.72%
call +4.72% · α +4.46%
$8.87
settled 3mo ago
T+20d
-15.11%
call -15.11% · α -12.93%
$7.19
settled 2mo ago
T+60d
-8.26%
call -8.26% · α -11.22%
$7.77
settled 7d ago

Price Chart

Loading chart...

Executive Summary

CorMedix Inc. dismissed its independent auditor CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY) as its new independent registered public accounting firm for FY2026. The change was approved by the Audit Committee on June 25, 2026, with no disagreements between the company and CBIZ, though a previously disclosed material weakness in internal controls over financial reporting was noted as a reportable event. The move from a mid-tier firm to a Big 4 auditor may signal a step up in audit quality, but the second auditor change in just over a year and the existing material weakness warrant caution.

Key Facts

  • CorMedix dismissed CBIZ CPAs P.C. as its independent auditor on June 25, 2026.
  • Appointed Ernst & Young LLP (EY) as the new independent auditor for the fiscal year ending December 31, 2026.
  • No disagreements (as defined in Item 304(a)(1)(iv)) occurred with CBIZ from April 17, 2025 through June 25, 2026.
  • A material weakness in internal control over financial reporting was disclosed as a reportable event, previously reported in the FY2025 10-K.
  • CBIZ agreed with the statements in the 8-K via Exhibit 16.1 letter dated July 1, 2026.

Financial Impact

No financial figures provided; the change in auditor does not directly impact reported financials.

internal controls

Risk Factors

  • Continued material weakness in internal controls could lead to restatements or delayed filings.
  • Further auditor changes may signal underlying accounting or governance issues.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001410098-26-000037
Exhibit: exhibit161letterfromcbiz.htm0001410098-26-000037
Document: 0001410098-26-000037-index-headers.html0001410098-26-000037
Document: 0001410098-26-000037-index.html0001410098-26-000037
Document: 0001410098-26-000037.txt0001410098-26-000037
12 reports for CRMD
Performance horizon
89% Hit rate 8 of 9 directional calls best @ T+60▲ +34.13%Mar 5, 2026
Filters
Rows
Reports for CRMD — sortable, filterable
TypeNow
Aug 13, 2026
7w ago
8-K
NEUTRAL ★ 5/10
$8.14 $7.83▼ −3.87%▼ −2.12%$7.19 (−11.67%)
Aug 13, 2026
7w ago
Press Release
NEUTRAL ★ 5/10
$8.14 $7.83▼ −3.87%▼ −2.12%$7.19 (−11.67%)
Jul 1, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$8.47 $7.19▼ −15.11%▼ −12.93%$7.19 (−15.11%)
Jun 12, 2026
16w ago
Institutional Cluster
BULLISH ★ 7/10
$8.74 $8.40▼ −3.89%▼ −5.67%$7.19 (−17.73%)
Jun 8, 2026
16w ago
8-K
BULLISH ★ 7/10
$8.54 $8.79▲ +2.93%▲ +1.30%$7.19 (−15.81%)
Jun 8, 2026
16w ago
Press Release
BULLISH ★ 7/10
$8.54 $8.79▲ +2.93%▲ +1.30%$7.19 (−15.81%)
May 14, 2026
20w ago
8-K
BULLISH ★ 7/10
$7.93 $8.74▲ +10.21%▲ +11.07%$7.19 (−9.33%)
May 14, 2026
20w ago
Press Release
BULLISH ★ 7/10
$7.93 $8.74▲ +10.21%▲ +11.07%$7.19 (−9.33%)
Apr 27, 2026
22w ago
8-K
BULLISH ★ 8/10
$7.82 $8.27▲ +5.75%▲ +0.80%$7.19 (−8.06%)
Apr 27, 2026
22w ago
Press Release
BULLISH ★ 8/10
$7.82 $8.27▲ +5.75%▲ +0.80%$7.19 (−8.06%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access